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ABSTRACT 
 
MCP-1 Directly Induces Renal Tubulointerstitial Fibrosis 
Independently of Monocytes/Macrophages Infiltration 
 
Hye-Young Kang 
 
Department of Medical Science 
The Graduate School, Yonsei University  
 
(Directed by Professor Shin-Wook Kang) 
 
 
 
Background: Previous studies have demonstrated the importance of monocyte 
chemoattractant protein-1 (MCP-1) and its receptor, C-C chemokine receptor 2 
(CCR2), in the pathogenesis of various inflammatory and fibrotic diseases via 
the recruitment and activation of monocytes/macrophages. Recently, however, 
accumulating in vitro evidence has indicated that MCP-1 per se may act directly 
on renal cells via CCR2. Therefore, the results of a number of former studies 
showing the impacts of MCP-1/CCR2 blockade on renal injury may be partly 
2 
attributed to a direct inhibitory effect of MCP-1 on renal cells, but it has never 
been clarified in vivo to date. Since all previous studies to explore the effect of 
MCP-1 on diverse renal diseases were performed using MCP-1-neutralizing 
antibody, CCR2 antagonist, or MCP-1 or CCR2 knockout technique, which 
accompanied a significant reduction in monocytes/macrophages infiltration 
within the kidney, it was hard to define whether the beneficial influence of 
MCP-1/CCR2 inhibition on renal injury was attributed to the direct inhibitory 
effect of MCP-1 on renal cells or was just a consequence of a significant 
decrease in inflammatory cells infiltration. 
 
Purpose: This study was undertaken to investigate the direct impact of the 
MCP-1/CCR2 on renal fibrosis in vivo by using 
monocytes/macrophages-depleted mice. In addition, the direct effect of MCP-1 
on extracellular matrix (ECM) synthesis along with the role of CCR2 was also 
examined in cultured tubular epithelial cells (NRK-52E). 
 
Methods: In vitro, NRK-52E cells were incubated in DMEM media containing 
5.6 mM glucose (Control, Con) or recombinant MCP-1 (10 ng/ml) with or 
without RS102895 (2 and 10 M), a specific chemical inhibitor of CCR2, and 
CCR2 siRNA (final concentrations: 10, 25, and 50 nM). After 72 hours, cells 
were harvested. In vivo, Thirty-six male C57BL/6J mice, weighting 25-30 g, 
were divided into six groups: Group 1, control mice treated with intravenous 
3 
PBS only (N = 6) (Control, Con); Group 2, mice injected with liposome vehicle 
(LV) and lenti-empty virus intravenously (N = 6); Group 3, mice with 
liposome-clodronate (LC) and lenti-empty virus (N = 6); Group 4, mice with LV 
and lenti-MCP-1 virus (N = 6); Group 5, mice with LC and lenti-MCP-1 virus 
(N = 6); and Group 6, mice with LC, lenti-MCP-1 virus, and RS102895 (N = 6). 
LV and LC in a volume of 200 µl PBS were injected intravenously every 5 days 
for 4 weeks, and lenti-empty and lenti-MCP-1 virus were injected intravenously 
at a dose of 1.5 x 10
7
 transfection units every 5 days, three times with LC or LV. 
RS102895 was delivered at a dose of 3 mg/kg/day for 4 weeks via 
subcutaneously-implanted osmotic mini-pumps. Either diphtheria toxin (DT) 
diluted in PBS (10 ng/g of body weight) (N = 24) or PBS (N = 6) was given 
intraperitoneally to Cd11b-diphtheria toxin receptor (DTR) mice on the day 
before lenti-MCP-1 virus injection and every 3 days. Lenti-MCP-1 was also 
injected at 3 days after the first administration. Six from DTR mice injected 
with lenti-MCP-1 virus and DT were treated with RS102895 (3 mg/kg/day) via 
osmotic mini-pumps. DTR mice were sacrificed at 10 days after the first 
lenti-MCP-1 virus injection. The protein expression of fibronectin, type I 
collagen and CCR2 in cultured NRK-52E cells, and the whole kidney were 
evaluated by Western blot, and the mRNA expression of fibronectin and type I 
collagen was assessed by real-time PCR. MCP-1 concentrations in serum and 
the whole kidney were determined by ELISA. Peripheral blood cell counts were 
conducted and immunohistochemistry (IHC) for fibronectin, type I collagen and 
4 
F4/80 and Masson’s trichrome staining were examined. 
 
Results: Compared to Con cells, the protein expression of fibronectin and type I 
collagen were significantly increased in NRK-52E cells exposed to MCP-1, and 
these increases were significantly abrogated by RS102895 or CCR2 siRNA (P < 
0.05). Two days after administration of LC and DT, there was a significant 
reduction in peripheral blood monocyte counts in C57BL/6J mice and DTR 
mice, respectively, compared to Con mice (P < 0.001). While administration of 
lenti-MCP-1 virus alone induced a significant increase in the number of 
infiltrated monocytes/macrophages in the kidney (P < 0.001), a concomitant 
treatment with LC or DT significantly attenuated the increase in 
monocytes/macrophages infiltration in the kidney (P < 0.001) compared to Con 
mice. The significant increases in fibronectin and type I collagen protein 
expression (P < 0.01), assessed by Western blot, in LC- or DT-treated mice 
infected with lenti-MCP-1 virus were significantly ameliorated by CCR2 
inhibition using osmotic mini-pumps containing RS102895 (P < 0.05). The 
significant increases in IHC staining scores for fibronectin and type I collagen 
within the tubulointerstitium in monocytes/macrophages-depleted mice infected 
with lenti-MCP-1 virus (P < 0.001) were significantly attenuated by RS102895 
treatment (P < 0.001). 
 
Conclusions: These findings suggest that the MCP-1/CCR2 system is directly 
5 
involved in MCP-1-induced renal fibrosis and blockade of the MCP-1/CCR2 
system can be a promising approach to treat various kidney diseases such as 
diabetic nephropathy, of which MCP-1-induced renal fibrosis is involved in the 
pathogenesis. 
 
 
 
 
---------------------------------------------------------------------------------------------------------- 
Key words: monocyte chemoattractant protein-1, renal proximal tubular epithelial cells, 
renal fibrosis, extracellular matrix, monocytes/macrophages 
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I. INTRODUCTION 
Inflammation is a pathophysiological response to infection or tissue injury
1
. 
Even though inflammation is fundamentally a beneficial host reaction, 
uncontrolled or persistent inflammatory process is known to contribute to the 
pathogenesis of chronic inflammatory diseases, including atherosclerosis
2
, 
systemic sclerosis
3
, rheumatoid arthritis
4
, and inflammatory bowel disease
5
. 
Chronic inflammation is also involved in the development and progression of 
various renal diseases such as diabetic nephropathy
6,7
, lupus nephritis
8
, and 
ischemia-reperfusion injury
9
. In all cases, monocytes/macrophages are the 
7 
principle cells found at the sites of inflammation. 
These cells extravasate from the bloodstream through a process mediated by 
chemokines secreted from resident cells. Chemokines are a family of 
chemotactic cytokines that induce the migration of various cell types; to date, 
more than 40 chemokines have been identified
10
. Among these, monocyte 
chemoattractant protein (MCP)-1 is the most extensively studied. MCP-1 and its 
receptor, C-C chemokine receptor 2 (CCR2), have been shown to play an 
important role in the pathogenesis of various inflammatory and fibrotic diseases 
via the recruitment and activation of monocytes/macrophages, which are known 
to release profibrotic cytokines such as transforming growth factor (TGF)-1, 
platelet-derived growth factor, and fibroblast growth factor, which in turn 
modifies the biology of resident cells
11-13
. Based on these facts, numerous 
investigations were performed and demonstrated that inhibition of the 
MCP-1/CCR2 system resulted in an improvement of a variety of renal 
diseases
13-19
. 
Recently, however, accumulating in vitro evidence has indicated that MCP-1 
per se may act directly on various somatic cells, including renal cells, via 
CCR2
14,20-24
. Previous studies found that MCP-1 induced not only the 
expression of intercellular adhesion molecule-1, fibronectin, and type IV 
collagen expression in cultured mesangial cells
20,21,24
 but also increased motility 
and apoptosis in cultured podocytes
23,25,26
. Therefore, the results of a number of 
former studies showing the impacts of MCP-1/CCR2 blockade on renal injury 
8 
may be partly attributed to a direct inhibitory effect of MCP-1 on renal cells, but 
it has never been clarified in vivo to date. Since all previous studies to explore 
the effect of MCP-1 on diverse renal diseases were performed using 
MCP-1-neutralizing antibody
27
, CCR2 antagonist
16,28-30
, or MCP-1
31
 or CCR2 
knockout technique
17,28,29
, which accompanied a significant reduction in 
monocytes/macrophages infiltration within the kidney, it was hard to define 
whether the beneficial influence of MCP-1/CCR2 inhibition on renal injury was 
attributed to the direct inhibitory effect of MCP-1 on renal cells or was just a 
consequence of a significant decrease in inflammatory cells infiltration. 
In this study, therefore, I tried to clarify the direct impact of the 
MCP-1/CCR2 system on renal fibrosis in vivo by using 
monocytes/macrophages-depleted mice. The direct effect of MCP-1 on 
extracellular matrix (ECM) synthesis along with the role of CCR2 was also 
examined in cultured tubular epithelial cells. 
 
 
 
9 
II. MATERIALS AND METHODS 
1. Cell culture 
Renal proximal tubular epithelial cells (NRK-52E) were used for cell culture 
experiments. NRK-52E cells were maintained in Dulbeco's Modified Eagle's 
Medium (DMEM) (Invitrogen, Carlsbad, CA, USA) media supplemented with 
5% fetal bovine serum (FBS), 100 U/ml penicillin, 100 mg/ml streptomycin, 
and 26 mM NaHCO3. Cells were grown at 37°C in humidified 5% CO2 in air. 
 
2. Inhibition of the MCP-1/CCR2 system 
In the current study, two different methods were utilized to block the 
MCP-1/CCR2 system in these cells; RS102895 (Sigma-Aldrich Corp., St Louis, 
MO, USA), a specific chemical inhibitor of CCR2, and pre-designed CCR2 
siRNA (Ambion, Austin, TX, USA). Purchased CCR2 siRNA was transfected 
with RNA imax (Invitrogen) according to the manufacturer’s protocol. 
Subconfluent NRK-52E cells were serum restricted for 24 hr, after which the 
media was replaced by 0.5% FBS DMEM containing 5.6 mM glucose (Control, 
Con) or recombinant MCP-1 (10 ng/ml) (R&D Systems, Minneapolis, MN, 
USA) with or without RS102895 (2 and 10 M) and CCR2 siRNA (final 
concentrations: 10, 25, and 50 nM). CCR2 siRNA had the following sequences: 
sense 5’-GGCUAAAAGUAGUGAAUGAtt-3’, antisense 
5’-UCAUUCACUACUUUUAGCCtt-3’. At 72 hr after media change, cells 
were harvested. The dose of MCP-1 used in the experiments was determined 
10 
based on the results of preliminary experiments. 
 
3. Generation of mouse MCP-1-expressing lentivirus 
The lentiviral vector used in the present study was an HIV-based bicistronic 
vector (GeneCopoeia, Germantown, MD, USA) designated as lenti-MCP-1-GFP, 
which carried a mouse MCP-1 gene driven by a cytomegalovirus (CMV) 
immediate-early promoter and an enhanced green fluorescent protein (GFP) 
reporter gene. Lenti-MCP-1-GFP vectors were prepared by transient 
transfection of human embryonic kidney (HEK) 293FT cells (Invitrogen) using 
a lenti-pac HIV expression kit (GeneCopoeia) according to the manufacturer’s 
protocol. Briefly, HEK 293FT cells were cultured in 10 cm tissue culture dishes 
(BD Biosciences, San Jose, CA, USA). When the cells became confluent, they 
were transfected with 2.5 μg of lentiviral plasmid along with 2.5 μg of the 
mixed envelope and packaging plasmids. The viral supernatants were harvested 
at 48 hr post-transfection, centrifuged at 780 g for 5 min, and filtered through a 
0.45 m pore size filter. After then, additional centrifugation was performed at 
83,000 g for 1.5 hr, and the resulting pellet was resuspended in 100 l of 
phosphate-buffered saline (PBS). Lentivirus titers were determined by infecting 
HEK 293FT cells with a dilution series of the viral suspension. 
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Figure 1. Vector map for the MCP-1-expressing lentiviral vector 
 
 
4. Animal studies 
All animal studies were conducted using a protocol approved by the 
Committee for the Care and Use of Laboratory Animals at Yonsei University 
College of Medicine, Seoul, Korea. Liposome-clodronate (LC), which is known 
to deplete peripheral monocytes/macrophages, was purchased from 
Sigma-Aldrich Corporation. Thirty-six male C57BL/6J mice, weighting 25-30g, 
were divided into six groups: Group 1, control mice treated with intravenous 
PBS only (N = 6) (Control, Con); Group 2, mice injected with liposome vehicle 
(LV) and lenti-empty virus intravenously (N = 6); Group 3, mice with LC and 
lenti-empty virus (N = 6); Group 4, mice with LV and lenti-MCP-1 virus (N = 6); 
Group 5, mice with LC and lenti-MCP-1 virus (N = 6); and Group 6, mice with 
12 
LC, lenti-MCP-1 virus, and RS102895 (N = 6). LV and LC in a volume of 200 
µl PBS were injected intravenously every 5 days for 4 weeks, and lenti-empty 
and lenti-MCP-1 virus were injected intravenously at a dose of 1.5 x 10
7
 
transfection units every 5 days, three times with LC or LV. RS102895 was 
delivered at a dose of 3 mg/kg/day for 4 weeks via subcutaneously-implanted 
osmotic mini-pumps (ALZET
®
 Osmotic Pumps; Durect Corp., Cupertino, CA, 
USA). 
Cd11b-diphtheria toxin receptor (DTR) mice on an FVB background [official 
symbol Tg (ITGAM-DTR/EGFP) 34Lan/J] were purchased from Jackson 
Laboratory (Bar Harbor, ME, USA). Transient depletion of macrophages was 
elicited by intraperitoneal administration of DT. The FVB-Tg 
(ITGAM-DTR/EGFP) 34Lan/J transgenic mice encode a DTR fused with GFP 
under the control of a human integrin αM (ITGAM) promoter (CD11b). Either 
DT (Sigma-Aldrich Corp.) diluted in PBS (10 ng/g of body weight) (N = 24) or 
PBS (N = 6) was given intraperitoneally to mice on the day before lenti-MCP-1 
virus injection and every 3 days. Lenti-MCP-1 was also injected at 3 days after 
the first administration. Six from DTR mice injected with lenti-MCP-1 virus 
and DT were treated with RS102895 (3 mg/kg/day) via osmotic mini-pumps. 
DTR mice were sacrificed at 10 days after the first lenti-MCP-1 virus injection. 
 
5. Peripheral blood cell counts 
Blood samples were taken three times; at the time of the first LV or DT 
13 
injection, 2 days after the first LV or DT injection, and at the time of sacrifice, 
and monocytes in the peripheral blood were determined. 
 
6. ELISA 
Serum and the whole kidney were used for the measurement of MCP-1. The 
kidney was washed in ice-cold PBS, snap-frozen in liquid nitrogen, pulverized 
with a mortar and pestle while frozen, and homogenized in 10 mM HEPES pH 
7.9, 10 mM KCl, 0.1 mM EGTA, 1 mM dithiothreithol (DTT), and a broad 
spectrum proteinase inhibitor cocktail (Boehringer Mannheim GmbH, 
Mannheim, Germany). 
The levels of MCP-1 were determined using commercial ELISA kits (R&D 
Systems) according to the manufacturer’s protocol as previously described. The 
kit for mouse MCP-1 was species-specific and sensitive up to 5.0 pg/ml. 
 
7. Total RNA extraction and reverse transcription 
Total RNA was extracted form cultured NRK-52E cells as previously 
described, and first strand cDNA was made by using a Boehringer Mannheim 
cDNA synthesis kit (Boehringer Mannheim GmbH). Two g of total RNA 
extracted from cultured cells was reverse transcribed using 10 mM random 
hexanucleotide primer, 1 mM dNTP, 8 mM MgCl2, 30 mM KCl, 50 mM 
Tris-HCl, pH 8.5, 0.2 mM DTT, 25 U RNAse inhibitor, and 40 U AMV reverse 
14 
transcriptase. The mixture was incubated at 30°C for 10 min and 42°C for 1 hr, 
followed by inactivation of enzyme at 99°C for 5 min. 
 
8. Real-time polymerase chain reaction (Real-time PCR) 
The primers used for fibronectin, type I collagen, and 18s amplification were 
as follows: fibronectin, sense 5’-TGACAACTGCCGTAGACCTG-3’, antisense 
5’-TACTGGTTGTAGGTGTGGCC-3’; type I collagen, sense 
5’-GCATGAGCCGAAGCTAACC-3’, antisense 
5’-GGAGGTCCACAAAGCTGAAC-3’; and 18s, sense 
5’-CCTGCGGCTTAATTTGACTC-3’, antisense 5’- 
AACTAAGAACGGCCATGCAC-3’. Using the ABI PRISM®  7700 Sequence 
Detection System (Applied Biosystems, Foster City, CA, USA), PCR was 
performed with a total volume of 20 μl in each well, containing 10 μl of SYBR 
Green
®
 PCR Master Mix (Applied Biosystems), 5 μl of cDNA corresponding to 
25 ng of RNA, and 5 pmol sense and antisense primers. Primer concentrations 
were determined by preliminary experiments that analyzed the optimal 
concentrations of each primer. The PCR conditions were as follows: 35 cycles 
of denaturation at 94.5°C for 30 sec, annealing at 60°C for 30 sec, and extension 
at 72°C for 1 min. Initial heating at 95°C for 9 min and final extension at 72°C 
for 7 min were performed for all PCR reactions. Each sample was run in 
triplicate in separate tubes and a control without cDNA was also run in parallel 
with each assay. After real-time PCR, the temperature was increased from 60 to 
15 
95°C at a rate of 2°C/min to construct a melting curve. The cDNA content of 
each specimen was determined using a comparative CT method with 2
-ΔΔCT
. The 
results were given as relative expression of fibronectin and type I collagen 
normalized to the the 18s rRNA and expressed in arbitrary units. Signals from C 
cells were assigned a relative value of 1.0. In pilot experiments, PCR products 
revealed a single band on agarose gels. 
 
9. Western blot analysis 
The protein expression of fibronectin, type I collagen, and CCR2 in cultured 
NRK-52E cells, and the whole kidney were evaluated by Western blot as 
previously described. Cultured cells and the homogenized whole kidney were 
lysed in sodium dodecyl sulfate (SDS) sample buffer [2% SDS, 10 mM 
Tris-HCl, pH 6.8, 10% (vol/vol) glycerol], treated with Laemmli sample buffer, 
heated at 100C for 5 min, and electrophoresed in a 10% acrylamide denaturing 
SDS-polyacrylamide gel. Proteins were then transferred to a Hybond-ECL 
membrane using a Hoeffer semidry blotting apparatus (Hoeffer Instruments, 
San Francisco, CA, USA), and the membranes were then incubated in blocking 
buffer A (1 x PBS, 0.1% Tween-20, and 8% nonfat milk) for 1 hr at room 
temperature, followed by an overnight incubation at 4C in a 1:1000 dilution of 
polyclonal antibodies to fibronectin (DAKO, Carpentaria, CA, USA), type I 
collagen (Southern Biotech, Birmingham, AL, USA), CCR2 (Abcam, 
Cambridge, UK), or -actin (Sigma-Aldrich Corp.). The membrane was then 
16 
washed once for 15 min and twice for 5 min in 1 x PBS with 0.1% Tween-20. 
Next, the membrane was incubated in buffer A containing a 1:1000 dilution of 
horseradish peroxidase-linked goat anti-rabbit or anti-mouse IgG (Santa Cruz 
Biotechnology, Inc.). The washes were repeated, and the membrane was 
developed with a chemiluminescent agent (ECL; Amersham Life Science, Inc., 
Arlington Heights, IL, USA). The band densities were measured using TINA 
image software (Raytest, Straubenhardt, Germany), and the changes in the 
optical densities of bands from the treated groups relative to Con cells or kidney 
were used in the analysis. 
 
10. Immunohistochemistry and Masson’s trichrome staining 
Slices of the kidney were fixed in 10% neutral-buffered formalin, processed 
in the standard manner, and 5 μm-thick sections of paraffin-embedded tissues 
were utilized for immunohistochemical (IHC) staining. Slides were 
deparaffinized, hydrated in ethyl alcohol, and washed in tap water. Antigen 
retrieval was carried out in 10 mM sodium citrate buffer for 20 min using a 
Black & Decker vegetable steamer. Primary antibodies for fibronectin and 
F4/80 (Santa Cruz Biotechnology, Inc.) were diluted to the appropriate 
concentrations with 2% casein in bovine serum albumin and then added to the 
slides, followed by an overnight incubation at 4°C. After washing, a secondary 
antibody was added for 20 min, and the slides were washed and incubated with 
a tertiary PAP complex for 20 min. Diaminobenzidine was added for 2 min and 
17 
the slides were counterstained with hematoxylin. For Masson’s trichrome 
staining, 5 μm-thick sections of paraffin-embedded tissues were deparaffinized, 
hydrated in ethyl alcohol, washed in tap water, and re-fixed in Bouin’s solution 
at 56°C for 1 hr. After washing in running tap water for 10 min and staining 
with Weigert’s iron hematoxylin working solution for 10 min, the sections were 
stained with Biebrich scarlet-acid fuchsin solution for 15 min, followed by a 
wash for 10 min. Next, the slides were then differentiated in 
phosphomolybdic-phosphotungstic acid solution for 15 min, transferred to 
aniline blue solution and stained for 10 min, and after then reacted with 1% 
acetic acid solution for 5 min. A semi-quantitative score of staining intensity 
was determined by examining at least twenty tubulointerstitial fields under x 
400 magnification. The positive-staining intensity of 1+ to 4+ compared with a 
negative control (score = 0), in which the IHC staining was performed without 
the primary antibodies, were defined by one investigator in a blinded fashion, 
based on the lightness and darkness of the brownish color using a digital image 
analyzer (MetaMorph version 4.6r5, Universal Imaging, Downingtown, PA). 
The staining score was obtained by multiplying the intensity of staining by the 
percentage of tubulointerstitium staining for that intensity; these numbers were 
then added for each experimental animal to give the staining score [= Σ 
(intensity of staining) x (% of tubulointerstitium with that intensity)]. The 
number of F4/80-positive cells was counted in at least 20 fields of the 
tubulointerstitium/section under x 400 magnification. 
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11. Statistical analysis 
All values are expressed as mean  standard error of the mean (SEM). 
Statistical analyses were performed using the Statistical Package for Social 
Sciences for Windows Ver. 11.0 (SPSS, Inc., Chicago, IL, USA). Results were 
analyzed using one-way ANOVA with post hoc test using Bonferonni’s method 
for multiple comparisons. P values less than 0.05 were considered statistically 
significant. 
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III. RESULTS 
1. MCP-1 increases fibronectin expression in NRK-52E cells 
First, I examined the impact of MCP-1 on fibronectin expression in cultured 
NRK-52E cells. The administration of recombinant MCP-1 significantly 
increased fibronectin protein expression in NRK-52E cells in a dose-dependent 
manner (P < 0.05) (Fig. 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. A representative Western blot for fibronectin protein in NRK-52E cells 
exposed to 5 ng/ml, 10 ng/ml, or 20 ng/ml MCP-1 (representative of five blots). 
MCP-1 significantly increased fibronectin protein expression in NRK-52E cells in a 
dependent manner. 
*; P < 0.05 vs. Con, #; P < 0.01 vs. Con 
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2. CCR2 inhibition ameliorates MCP-1-induced fibronectin and type I 
collagen expression 
Second, to clarify the role of CCR2 in MCP-1-induced fibronectin expression, 
the cells were treated with RS102895, a chemical inhibitor of CCR2, or CCR2 
siRNA. The efficacy of CCR2 siRNA transfection was evaluated by 
determining the protein expression of CCR2. As shown in Fig. 3, CCR2 protein 
expression was significantly decreased in CCR2 siRNA-transfected NRK-52E 
cells in a dose-dependent manner (P < 0.05). In contrast, a negative control of 
the CCR2 siRNA had no effect on the expression of CCR2 protein. 
The administration of 10 ng/ml recombinant MCP-1 significantly increased 
the expression of fibronectin and type I collagen protein in cultured NRK-52E 
cells. The protein expression of fibronectin and type I collagen were 4.1- and 
2.8-fold higher in MCP-1-treated NRK-52E cells, respectively, compared to 
Con cells (P < 0.01), and these increases in fibronectin and type I collagen 
protein expression were significantly attenuated by CCR2 inhibition with 10 
μM RS102895 or 25 nM CCR2 siRNA (P < 0.01) (Fig. 4A), suggesting that 
MCP-1 directly induced fibronectin and type I collagen protein expression in 
NRK-52E cells via CCR2. Meanwhile, MCP-1 had no effect on the expression 
of CCR2 protein in these cells. 
  Real-time PCR also revealed that MCP-1 significantly increased fibronectin 
and type I collagen mRNA expression (P < 0.01), which were significantly 
abrogated by 10 μM RS102895 or 25 nM CCR2 siRNA (P < 0.01) (Fig. 4B).  
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Figure 3. A representative Western blot for CCR2 protein in NRK-52E cells 
transfected with 10, 25, or 50 nM CCR2 siRNA (representative of five blots). CCR2 
protein expression was significantly decreased in CCR2 siRNA-transfected NRK-52E 
cells in a dose-dependent manner. In contrast, a negative control of CCR2 siRNA (50 
nM) had no effect on CCR2 protein expression.  
*; P < 0.05 vs. Con, #; P < 0.001 vs. Con 
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Figure 4. Fibronectin and type I collagen expression in NRK-52E cells exposed to 
10 μM RS102895 (RS), 25 nM CCR2 siRNA (siRNA), 10 ng/ml MCP-1 (MCP-1), 
MCP-1+RS, or MCP-1+siRNA. (A) A representative Western blot for fibronectin and 
type I collagen (representative of five blots). The protein expression of fibronectin and 
type I collagen were significantly increased in NRK-52E cells exposed to MCP-1, and 
these increases were significantly abrogated by RS or siRNA. (B) Real-time PCR also 
revealed that MCP-1 significantly increased fibronectin and type I collagen mRNA 
expression, which were significantly abrogated by 10 μM RS102895 or 25 nM CCR2 
siRNA.  
*; P < 0.01 vs. Con, †; P < 0.05 vs. MCP-1, #; P < 0.01 vs. MCP-1 
B 
A 
FN 
ColⅠ 
β-actin 
Con RS siRNA MCP-1 
MCP-1  
+RS 
   MCP-1 
+ siRNA 
  
C
on R
S
si
R
N
A
M
C
P
-1
M
C
P
-1
 +
R
S
M
C
P
-1
 +
 s
iR
N
A
0
1
2
3
4
F
ib
ro
n
e
c
ti
n
 /
 1
8
s
 r
a
ti
o
C
on R
S
si
R
N
A
M
C
P
-1
M
C
P
-1
 +
 R
S
M
C
P
-1
 +
 s
iR
N
A
0
1
2
3
C
o
ll
a
g
e
n
 I
 /
 1
8
s
 r
a
ti
o
C
on R
S
si
R
N
A
M
C
P
-1
M
C
P
-1
 +
 R
S
M
C
P
-1
 +
 s
iR
N
A
0
1
2
3
4
5
F
ib
ro
n
e
c
ti
n
 /
 β
-a
c
ti
n
 r
a
ti
o
C
on R
S
si
R
N
A
M
C
P
-1
M
C
P
-1
 +
 R
S
M
C
P
-1
 +
 s
iR
N
A
0
1
2
3
4
C
o
ll
a
g
e
n
 I
 /
 β
-a
c
ti
n
 r
a
ti
o 
† 
 # 
 
# 
 
# 
 
# # 
† 
 
† 
 
23 
3. MCP-1-expressing lentivirus increases MCP-1 protein both in vitro and 
in vivo 
Next, to test the efficacy of MCP-1-expressing lentivirus, the levels of 
MCP-1 were assessed in NRK-52E cells infected with lenti-MCP-1 virus, and 
in serum and the whole kidney collected from mice injected with lenti-MCP-1 
virus by Western blot and ELISA, respectively. MCP-1 protein expression was 
significantly increased in lenti-MCP-1-infected NRK-52E cells compared to 
Con cells (P < 0.001) (Fig. 5A). MCP-1 concentrations in serum and the whole 
kidney were also significantly higher in LC or DT-treated mice, in which 
peripheral monocytes/macrophages were depleted, injected with lenti-MCP-1 
virus compared to Con mice (P < 0.01) (Fig. 5B, C). 
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Figure 5. The levels of MCP-1 in NRK-52E cells infected with lenti-MCP-1 virus, 
and in serum and the whole kidney collected from mice injected with lenti-MCP-1 
virus. (A) A representative Western blot for MCP-1 in NRK-52E cells infected with 
lenti-empty or lenti-MCP-1 virus (representative of five blots). The protein expression 
of MCP-1 was significantly increased in lenti-MCP-1-infected NRK-52E cells, while 
lenti-empty virus had no effect on MCP-1 protein expression. (B) MCP-1 levels, 
assessed by ELISA, in mice treated with PBS (Con), liposome vehicle 
(LV)+lenti-empty, liposome-clodronate (LC)+lenti-empty, LV+lenti-MCP-1, or 
LC+lenti-MCP-1. There were significant increases in MCP-1 concentrations in serum 
and the whole kidney of mice treated with LV+lenti-MCP-1 compared to Con, but these 
increases were not affected by LC. (C) MCP-1 levels, assessed by ELISA, in 
Cd11b-diphtheria toxin receptor (DTR) mice treated with PBS (Con), DT, 
DT+lenti-empty, lenti-MCP-1, or DT+lenti-MCP-1. There were significant increases in 
MCP-1 levels in serum and the whole kidney of mice treated with DT+lenti-MCP-1 
compared to Con, but DT had no impact on these increases. 
*; P < 0.001 vs. Con, #; P < 0.01 vs. Con 
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4. LC and DT nearly deplete peripheral blood monocytes, and 
macrophages infiltration in the kidney 
Two days after intravenous administration of LC, there was a significant 
reduction in peripheral blood monocyte counts (P < 0.001) (Fig. 6A). The 
proportions of monocytes were 5.6 ± 0.8% and 6.2 ± 0.3% in PBS- and 
LV-treated mice, respectively, while it was significantly decreased to 1.0 ± 0.2% 
after LC treatment. Similar finding was observed in DT-injected mice (P < 
0.001) (Fig. 6B). 
Ablation of monocyte/macrophage was also confirmed in the kidney by IHC 
staining for F4/80. While administration of lenti-MCP-1 virus alone induced a 
significant increase in the number of infiltrated monocytes/macrophages in the 
kidney (P < 0.001), a concomitant treatment with LC or DT significantly 
attenuated the increase in monocytes/macrophages infiltration in the kidney (P 
< 0.001) (Fig. 7). 
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Figure 6. Monocyte counts in the peripheral blood. (A) Monocyte counts in mice 
treated with PBS (Con), liposome vehicle (LV), or liposome-clodronate (LC). Two days 
after intravenous administration of LC, there was a significant reduction in peripheral 
blood monocyte counts. (B) Monocyte counts in in Cd11b-diphtheria toxin receptor 
(DTR) mice treated with PBS (Con) or DT. Compared to Con, peripheral blood 
monocyte counts were significantly decreased in DT-treated mice. 
*; P < 0.001 vs. Con 
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Figure 7. Immunohistochemical staining for F4/80 with the kidney tissue. (A) A 
representative photograph of the renal tubulointerstitium in mice treated with PBS 
(Con), liposome vehicle (LV)+lenti-empty, liposome-clodronate (LC)+lenti-empty, 
LV+lenti-MCP-1, or LC+lenti-MCP-1. Lenti-MCP-1 infection significantly increased 
macrophage infiltration within the kidney, which was significantly ameliorated by LC. 
(B) A representative photograph of the renal tubulointerstitium in Cd11b-diphtheria 
toxin receptor (DTR) mice treated with Con, DT, DT+lenti-empty, lenti-MCP-1, or 
DT+lenti-MCP-1. Macrophage infiltration within the kidney induced by lenti-MCP-1 
was significantly attenuated in mice treated with DT (x 400). 
*; P < 0.001 vs. Con, #; P < 0.001 vs. LV+lenti-MCP-1 or lenti-MCP-1 
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5. Lenti-MCP-1 virus induces ECM accumulation in the kidney 
independently of monocytes/macrophages infiltration 
Compared to Con mice, fibronectin and type I collagen protein expression in 
the kidney, assessed by Western blot and IHC staining, were significantly 
increased in mice infected by not only lenti-MCP-1 virus but also lenti-MCP-1 
virus with LC (P < 0.01) (Fig. 8A, B). The protein expression of fibronectin and 
type I collagen was also significantly increased in mice infected by lenti-MCP-1 
virus along with saline or DT compared to Con mice, even though 
monocytes/macrophages were nearly ablated by DT (P < 0.01) (Fig. 8C, D). In 
contrast, lenti-empty virus had no effect on fibronectin or type I collagen 
protein expression in mice. Masson’s trichome staining showed a similar pattern 
(Fig. 8B, D). 
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Figure 8. ECM protein expression by lenti-MCP-1 virus in the kidney of 
monocytes/macrophages-depleted mice. (A) A representative Western blot for 
fibronectin and type I collagen in mice treated with PBS (Con), liposome vehicle 
(LV)+lenti-empty, liposome-clodronate (LC)+lenti-empty, LV+lenti-MCP-1, or 
LC+lenti-MCP-1 (representative of five blots). Fibronectin and type I collagen protein 
expression were significantly increased in not only LV+lenti-MCP-1 but also 
LC+lenti-MCP-1 mice compared to Con mice. (B) Immunohistochemical staining for 
fibronectin and type I collagen, and Masson’s trichrome staining also revealed that the 
protein expression of fibronectin and type I collagen, and fibrosis, respectively, were 
significantly increased in mice infected with lenti-MCP-1. Even though LC nearly 
depleted macrophages infiltration within the kidney, it had no effect on fibronectin and 
type I collagen expression, or fibrosis in lenti-MCP-1-injected mice (x 400). (C) A 
representative Western blot for fibronectin and type I collagen in Cd11b-diphtheria 
toxin receptor (DTR) mice treated with Con, DT+lenti-empty, lenti-MCP-1, or 
DT+lenti-MCP-1 (representative of five blots). The expression of fibronectin and type I 
collagen protein were significantly increased in lenti-MCP-1 as well as 
DT+lenti-MCP-1 mice compared to Con mice. (D) Immunohistochemical staining for 
fibronectin and type I collagen, and Masson’s trichrome staining also demonstrated that 
fibronectin and type I collagen protein expression, and fibrosis, respectively, were 
significantly increased in mice injected with lenti-MCP-1 or DT+lenti-MCP-1, although 
monocytes/macrophages were nearly ablated by DT (x 400). 
*; P < 0.01 vs. Con, #; P < 0.001 vs. Con 
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6. CCR2 inhibitor abrogates MCP-1-induced ECM accumulation in the 
kidney 
The significant increases in fibronectin and type I collagen protein expression 
(P < 0.01), assessed by Western blot, in LC- or DT-treated mice infected with 
lenti-MCP-1 virus were significantly ameliorated by CCR2 inhibition using 
osmotic mini-pumps containing RS102895 (P < 0.05) (Fig 9A, 9C). IHC 
staining for fibronectin and type I collagen protein also confirmed the Western 
blot findings. The significant increases in IHC staining scores for fibronectin 
and type I collagen within the tubulointerstitium in 
monocytes/macrophages-depleted mice infected with lenti-MCP-1 virus (P < 
0.001) were significantly attenuated by RS102895 treatment (P < 0.001) (Fig. 
9B, 9D). 
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Figure 9. The effect of CCR2 inhibition on lenti-MCP-1 virus-induced ECM 
protein expression in the kidney regardless of monocytes/macrophages infiltration. 
(A) A representative Western blot for fibronectin and type I collagen in mice treated 
with PBS (Con), liposome-clodronate (LC)+lenti-empty, LC+lenti-MCP-1, or 
LC+lenti-MCP-1+RS102895 (3 mg/kg/day) (RS) (representative of five blots). The 
significant increases in the protein expression of fibronectin and type I collagen induced 
by MCP-1 were significantly ameliorated in LC+lenti-MCP-1 mice treated by RS. (B) 
Immunohistochemical staining for fibronectin and type I collagen, and Masson’s 
trichrome staining also found that MCP-1-induced fibronectin and type I collagen 
protein expression, and fibrosis, respectively, were significantly attenuated by RS (x 
400). (C) A representative Western blot for fibronectin and type I collagen in 
Cd11b-diphtheria toxin receptor (DTR) mice treated with Con, DT+lenti-empty, 
DT+lenti-MCP-1, or DT+lenti-MCP-1+RS (representative of five blots). The significant 
increases in the expression of fibronectin and type I collagen protein in 
DT+lenti-MCP-1-injected mice were significantly inhibited by RS treatment. (D) 
Immunohistochemical staining for fibronectin and type I collagen, and Masson’s 
trichrome staining also showed that the increases in the protein expression of 
fibronectin and type I collagen, and fibrosis, respectively, in DT+lenti-MCP-1 mice 
were significantly abrogated by the administration of RS (x 400). 
*; P < 0.01 vs. Con, #; P < 0.05 vs. LC+lenti-MCP-1 or DT+lenti-MCP-1, †; P < 0.001 
vs. Con, $; P < 0.001 vs. LC+lenti-MCP-1 
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IV. DISCUSSION 
MCP-1, a well-known chemokine, and its receptor CCR2 have been found to 
be involved in the pathogenesis of various kidney diseases via the recruitment 
of monocytes/macrophages
13-16,19
. Recently, however, accumulating in vitro 
evidence indicates that the MCP-1/CCR2 system per se has a direct effect on 
renal cells
20-24
. In this study, I demonstrate for the first time that MCP-1 
increases ECM synthesis in cultured renal tubular epithelial cells. In addition, 
the results of my in vivo experiments show that enhanced MCP-1 expression in 
the kidney is associated with ECM accumulation even in the absence of 
monocytes/macrophages infiltration.  
Previous clinical and experimental studies have suggested that the 
MCP-1/CCR2 system plays a major role in the development of numerous 
diseases in the whole body, including inflammatory bowel disease
5
, 
atherosclerosis
2
, asthma
32
, ischemia-related neuronal death
33
, systemic sclerosis
3
, 
and rheumatoid arthritis
4
. Regarding the kidney diseases, specifically, it is 
known to be involved in the pathogenesis of diabetic nephropathy
16,19
, lupus 
nephritis
8
, ischemia-reperfusion injury
9
, and crescentic glomerulonephritis
14
. 
The levels of urinary MCP-1, which represents intrarenal MCP-1 production, 
were significantly increased in diabetic patients with overt nephropathy and 
advanced tubulointerstitial lesions
34,35
. There was also a significant association 
of urinary MCP-1 levels with the percentage of crescents and the number of 
CD68-positive infiltrating cells in the interstitium in patients with crescentic 
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glomerulonephritis
36
. Furthermore, urinary MCP-1 was revealed to be an 
independent marker of renal function decline in diabetic and non-diabetic 
proteinuric diseases
37
. Since an increase in MCP-1 expression is demonstrated 
mainly in the tubulointerstitial area in diverse renal disease, including diabetic 
nephropathy
35,38
, lupus nephritis
39,40
, and IgA nephropathy
41
, and the severity of 
tubulointerstitial lesions correlates with the renal function better than the extent 
of glomerular injury
42
, it is inferred that MCP-1 contributes to the development 
of tubulointerstitial injury in a variety of renal diseases. The results of the 
current study showed that MCP-1-expressing lentivirus increased fibronectin 
and type I collagen expression in cultured tubular epithelial cells. Intravenous 
injection of MCP-1-expressing lentivirus to mice also successfully induced 
MCP-1 expression in the kidney, which was accompanied with ECM 
accumulation and monocytes/macrophages infiltration. In addition, these 
changes in ECM protein expression were abrogated by a CCR2 inhibitor. Taken 
together, I assumed that overexpression of MCP-1 in tubular epithelial cells 
both in vitro and in vivo led to an increase in ECM synthesis via CCR2. 
MCP-1 recruits and activates monocytes/macrophages. These infiltrated 
inflammatory cells are known to release profibrotic cytokines such as 
transforming growth factor (TGF)-1, platelet-derived growth factor, and 
fibroblast growth factor
43-45
, which in turn stimulates the resident cells to 
synthesize ECM. In the kidney, like other organs, enhanced MCP-1 expression 
was associated with an increase in inflammatory cells infiltration and ECM 
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accumulation
11-13
. Based on these findings, innumerous investigations have been 
performed to explore the effect of MCP-1/CCR2 inhibition on renal diseases. 
Treatment with a neutralizing antibody to MCP-1 significantly reduced 
proteinuria and interstitial fibrosis in an animal model of nephrotoxic 
nephritis
46-48
. Tubulointerstitial injury associated with nephrotoxic serum 
nephritis was also significantly ameliorated in MCP-1-deficient mice
49
. 
Moreover, either N-terminal deletion mutant of the human MCP-1 gene (7ND); 
which was constructed to competitively inhibit native MCP-1 action
50
, or a 
CCR2 inhibitor significantly attenuated ECM accumulation in animals with 
renal fibrosis induced by unilateral ureteral obstruction (UUO)
13
. Furthermore, 
renal interstitial fibrosis along with albuminuria was significantly abrogated in 
MCP-1-deficient animal models of type 1
19,21
 and type 2 diabetes
51
. Similarly, 
CCR2 knockout mice were significantly protected from renal injury induced by 
diabetes
52,53
, systemic lupus erythematosus
17
, ischemia-reperfusion
29
, or UUO
28
. 
All these beneficial effects of inhibiting the MCP-1/CCR2 system were 
accompanied by a significant reduction in monocytes/macrophages infiltration 
within the kidney, suggesting monocytes/macrophages were mainly responsible 
for these renal injuries. 
Recently, however, mounting in vitro evidence shows that MCP-1 exerts 
direct effects on renal cells via CCR2
14,21-24
. MCP-1 increased intercellular 
adhesion molecule-1 (ICAM-1) and fibronectin expression in cultured 
mesangial cells
20
. In addition, the MCP-1/CCR2 system was found to be 
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involved in apoptosis
23
, cellular motility
25,26
, rearrangement of the actin 
cytoskeleton
54
, and albumin permeability
26
 in cultured podocytes. Nephrin 
mRNA and protein expression was also significantly decreased in 
MCP-1-treated podocytes
31
. In cultured tubular epithelial cells, moreover, 
MCP-1 binding to CCR2 stimulated interleukin-6 secretion and ICAM-1 
synthesis in a time- and dose-dependent manner
55
, and induced 
epithelial-mesenchymal transition through the ERK pathway
56
. The present 
study demonstrated for the first time that MCP-1 directly induced fibronectin 
mRNA and protein expression in cultured tubular epithelial cells, and this 
increase in fibronectin expression was significantly ameliorated by a CCR2 
inhibitor. Considering the results of the previous and present studies, it was 
surmised that the beneficial in vivo effect of MCP-1/CCR2 inhibition on 
experimental renal diseases could be attributed to the alleviation of the 
deleterious impact of MCP-1 on renal cells rather than reduced inflammatory 
cells infiltration. 
To verify this hypothesis, two different methods were employed to exclude 
the influence of monocytes/macrophages in the kidney overexpressed with 
MCP-1. First, DTR transgenic mice were used. Since Duffield et al developed 
this transgenic mouse
57
, it has been widely used to investigate the role of 
monocytes/macrophages in renal injury induced by diabetic nephropathy
58
, 
UUO
59
, and nephrotoxic serum
60
. DT injection to DTR transgenic mice 
significantly reduced the number of monocytes/macrophages in the peripheral 
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blood and kidney, but the concomitant administration of DT and 
MCP-1-expressing lentivirus significantly increased the mortality after 15 days. 
Therefore, the experiments with DTR transgenic mice were completed at 10 
days. Second, LC was used. Even though neutrophil depletion and ineffective 
depletion of monocytes/macrophages in some tissues have been reported with 
LC
61,62
, this procedure has also been widely applied to explore the influence of 
monocytes/macrophages in various experimental renal diseases, including acute 
glomerulonephritis
63
, acute kidney injury associated with 
ischemia-reperfusion
64,65
, and renal interstitial fibrosis induced by UUO
66,67
. In 
this study, monocytes/macrophages were nearly completely depleted in the 
peripheral blood and kidney by the administration of LC, which was in 
accordance with the results of previous studies
63-67
. Furthermore, I observed that 
renal ECM protein expression was significantly increased in mice injected with 
MCP-1-expressing lentivirus, and this increase still remained significant even 
when monocytes/macrophages were depleted. These findings suggest that 
MCP-1 per se induces renal tubulointerstitial fibrosis in vivo, regardless of 
inflammatory cells infiltration. 
In summary, mRNA and protein expression of fibronectin and type I collagen 
were significantly increased by MCP-1 in cultured NRK-52E cells via CCR2. In 
addition, MCP-1 induced renal tubulointerstitial fibrosis, independently of 
monocytes/macrophages infiltration within the kidney. These findings suggest 
that blockade of the MCP-1/CCR2 system can be a promising approach to treat 
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various kidney diseases such as diabetic nephropathy, of which MCP-1-induced 
renal fibrosis is involved in the pathogenesis. 
44 
V. CONCLUSION 
MCP-1 significantly increased mRNA and protein expression of fibronectin 
and type I collagen in cultured renal tubular epithelial cells and in mouse kidney 
via CCR2 independently of monocytes/macrophages infiltration. These findings 
suggest that blockade of the MCP-1/CCR2 system can be a promising approach 
to treat various kidney diseases such as diabetic nephropathy, of which 
MCP-1-induced renal fibrosis is involved in the pathogenesis. 
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ABSTRACT (IN KOREAN) 
 
 
MCP-1/CCR2 시스템이 신섬유화에 미치는 직접적 영향 
 
<지도교수 강신욱> 
 
연세대학교 대학원 의과학과 
 
강 혜 영 
 
 
배경: 조직 내 단핵구/대식세포의 침윤은 염증반응에서 흔히 관찰되는 
소견으로, 이러한 세포들의 침윤을 통하여 염증반응 및 섬유화가 
동반되는 각종 질환이 발생하거나 진행되는 것으로 알려져 있다. 
단핵구/대식세포의 침윤은 주화성 물질의 유도에 의하여 일어나게 
되는데, 이러한 물질 중에서 가장 대표적인 것이 monocyte 
chemoattractant protein-1 (MCP-1)이다. 최근의 연구들에 의하면 일부 
세포에서 MCP-1의 수용체인 CCR2의 존재가 확인되었으며, MCP-1이 
염증세포의 침윤 유도 이외에도 이들 세포에 직접적으로 작용하는 
것으로 알려져 있다. 그러나, 현재까지 MCP-1의 병인적 역할을 
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규명한 모든 국내외 연구들을 보면, MCP-1 또는 CCR2 녹아웃 마우스, 
MCP-1 중화 항체, 그리고 CCR2 차단제 등을 사용하였을 뿐만 아니라 
모든 경우에서 염증세포의 침윤이 감소되었기 때문에, MCP-1/CCR 
시스템의 억제로 인한 효과가 염증세포의 침윤 감소로 인한 결과인지 
아니면 각종 세포에서 MCP-1/CCR2 억제의 직접적인 결과인지를 
감별할 수 없었다. 
 
목적: 본 연구에서는 단핵구/대식세포의 영향이 배제된 상태에서 
MCP-1/CCR2 시스템이 신섬유화에 미치는 직접적인 영향을 생체 
내외 실험을 통하여 알아보고자 하였다. 
방법: 생체 외 실험으로는 신세뇨관 세포를 대조군과 MCP-1 투여군 
(10 ng/ml)으로 나누어 배양하였으며, CCR2 억제제인 RS102895 (2 및 
10 M) 또는 CCR2 siRNA (10, 25 및 50 nM)를 함께 처치한 실험도 
하였다. 처치 72시간 후 각 군에서 세포를 수집하였다. 생체 내 
실험으로는 두 가지 모델의 마우스를 사용하였다. 첫 번째 모델은 
C57BL/6J 마우스로 36 마리를 6 그룹으로 나누었다: 그룹 1, 대조군 
(PBS) (N = 6) (Control, Con); 그룹 2, liposome vehicle (LV) + lenti-empty 
virus 투여군 (N = 6); 그룹 3, liposome-clodronate (LC) + lenti-empty virus 
투여군 (N = 6); 그룹 4, LV + lenti-MCP-1 virus 투여군 (N = 6); 그룹 5, 
LC + lenti-MCP-1 virus 투여군 (N = 6); 그리고 그룹 6, LC + lenti-MCP-1 
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virus + RS102895 투여군 (N = 6). LV와 LC는 200 µl PBS 용액에 
혼합하여 5일 간격으로 4주간 꼬리정맥을 통하여 주사하였으며, 
lenti-empty와 lenti-MCP-1 virus (1.5 x 107 transfection units)는 5일 
간격으로 3회 꼬리정맥으로 주사되었다. RS102895 (3 mg/kg/day)는 피하 
내로 삽입된 osmotic mini-pump를 이용하여 4주간 투여되었다. 두 번째 
모델은 Cd11b-diphtheria toxin receptor (DTR) 마우스로, 이 형질전환 
마우스에 DT를 투여하면 말초혈액 내 단핵구/대식세포가 제거된다. 
DT (N = 18) 또는 PBS (N = 6)를 3일 간격으로 복강 내로 투여하였으며, 
첫 투여 1일과 3일 후 lenti-MCP-1 virus를 꼬리정맥으로 주입하였다. 
DT + lenti-MCP-1 virus를 투여한 마우스 중 6 마리에는 RS102895 (3 
mg/kg/day)가 투여되었다. DTR 마우스는 첫 lenti-MCP-1 virus 투여 
10일 후 희생하여 샘플을 채취하였다. 신세뇨관 세포와 신장 조직 내 
fibronectin, type I collagen, 그리고 CCR2의 단백 발현은 Western blot을 
이용하여 분석하였으며, fibronectin과 type I collagen의 mRNA 발현은 
real-time PCR로 평가하였다. 혈청과 신장 조직 내 MCP-1 농도는 
ELISA를 이용하여 측정하였으며, 말초혈액 내 단핵구 수를 
확인하였다. 신섬유화 정도는 fibronectin과 type I collagen 항체를 
이용한 면역 조직화학 염색과 Masson’s trichrome 염색으로 
관찰하였다. 
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결과: MCP-1으로 자극한 신세뇨관 세포에서 fibronectin과 type I 
collagen의 단백 발현은 대조군에 비하여 의미있게 증가되었으며, 
이러한 증가는 RS102895 또는 CCR2 siRNA에 의하여 의의있게 
억제되었다. 대조군에 비하여 C57BL/6J 마우스에 LC를 투여하거나 
DTR 마우스에 DT를 투여한 2일 후 말초혈액 내 단핵구가 유의하게 
감소되었다. Lenti-MCP-1 virus 투여로 신장 조직 내 단핵구/대식세포의 
침윤은 의미있게 증가되었으나, LC 또는 DT를 동시에 투여한 
경우에는 신장 조직 내 단핵구/대식세포의 침윤이 의의있게 
감소되었다. Lenti-MCP-1 virus 단독 투여군 뿐만 아니라 lenti-MCP-1 
virus와 LC 또는 DT 동시에 투여한 마우스에서 fibronectin과 type I 
collagen의 단백 발현이 대조군에 비하여 유의하게 증가되었고, 이러한 
증가는 CCR2 억제제인 RS102895에 의하여 의미있게 억제되었다. 
면역 조직화학 염색 결과상 단핵구/대식세포의 침윤이 배제된 LC 
또는 DT 투여 마우스에서도 fibronectin과 type I collagen의 발현이 
의의있게 증가되었으며, 이러한 증가는 RS102895에 의하여 유의하게 
억제되었다. 
 
결론: 이상의 결과를 종합하여 볼 때, MCP-1/CCR2 시스템이 신세뇨관 
세포에 직접적으로 작용하여 신섬유화를 유도할 것으로 생각되며, 
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MCP-1/CCR2 시스템의 억제가 MCP-1이 병태생리에 관여하는 것으로 
알려져 있는 각종 신질환의 발생 및 진행 억제에 유용할 것으로 
사료된다. 
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